AtaiBeckley Joins S&P Total Market and Completion Indices, Prompting $3 Trillion Passive Fund Buys
AtaiBeckley will join the S&P Total Market, S&P Completion and CRSP U.S. benchmark indices on March 23, triggering passive funds tracking over $3 trillion in assets to build positions. The inclusion follows its December 2025 addition to the Nasdaq Biotechnology Index and coincides with Phase 3 initiation of BPL-003 in Q2 2026.
1. Index Inclusion
AtaiBeckley will join the S&P Total Market Index, S&P Completion Index and CRSP U.S. benchmark indices effective March 23, 2026, expanding its footprint across broad-market passive strategies.
2. Passive Fund Mandates
Inclusion triggers mandatory buying by passive funds tracking over $3 trillion in combined assets, including the world’s largest mutual fund, boosting liquidity and investor base.
3. Pipeline Milestones
AtaiBeckley’s BPL-003 Phase 3 program remains on track for Q2 2026 initiation, while topline data for VLS-01 Phase 2b are expected in H2 2026, reflecting clinical pipeline momentum.
4. Market Profile Expansion
These index additions build on the December 2025 Nasdaq Biotechnology Index inclusion and follow the company’s U.S. redomiciliation, enhancing visibility among institutional investors.